Immune System News and Research

RSS

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

Three-drug combination produces better results in multiple myeloma patients

In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.

7 Dec 2014

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Comb-shaped polymers efficiently protect proteins in vivo

An enzyme that usually triggers strong allergic reactions now circulates in the veins of a group of mice without alerting the immune system. As INRS Énergie Matériaux Télécommunications Research Centre Professor Marc A. Gauthier explains in an article published in the journal Nature Communications, a polymer was used to camouflage the enzyme before it was injected into the rodents. This was achieved by coating the enzyme to avoid an immune response in a manner that does not compromise its activity.

6 Dec 2014

Study sheds new light on well-known mechanism required for immune response

A new study published in the scientific journal Proceedings of the National Academy of Sciences of the United States of America sheds new light on a well-known mechanism required for the immune response. Researchers at the IRCM, led by Tarik Möröy, PhD, identified a protein that controls the activity of the p53 tumour suppressor protein known as the "guardian of the genome".

6 Dec 2014

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences.

5 Dec 2014

Researchers discover essential role of intestinal immune system in controlling energy metabolism

A group of UCL researchers (Louvain Drug Research Institute) identified an unsuspected mechanism impacting the development of obesity and diabetes type 2 after following a diet with a high dose of fat nutrition.

5 Dec 2014

Simple treatments for Ebola patients not given sufficient priority

The widespread misconception that there are no proven treatments for Ebola virus disease has meant that simple treatments – especially intravenous fluids and electrolytes, which could reduce the number of deaths caused by the virus – have been neglected, according to a new Comment, published in The Lancet.

5 Dec 2014

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.

5 Dec 2014

Immune System News and Research

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Researchers identify new targets for future CLL therapies

Nivolumab drug highly effective for Hodgkin's lymphoma

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Novel treatments show promising results in patients with different hematologic disorders

Study: Key protein may help prevent tumor growth, promote wound healing

Three-drug combination produces better results in multiple myeloma patients

Innovative cell therapy shows highly promising results in pediatric patients with ALL

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Comb-shaped polymers efficiently protect proteins in vivo

Study sheds new light on well-known mechanism required for immune response

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

Researchers discover essential role of intestinal immune system in controlling energy metabolism

Simple treatments for Ebola patients not given sufficient priority

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Scientists uphold mouse model of human disease, but pinpoint vital differences in gene expression

Research to Prevent Blindness, IRRF partner to advance knowledge about AMD

Melbourne researcher wins Sornchai Looareesuwan Medal for research on malaria

Immunology eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News